JP2002522355A5 - - Google Patents

Info

Publication number

JP2002522355A5

JP2002522355A5 JP2000531179A JP2000531179A JP2002522355A5 JP 2002522355 A5 JP2002522355 A5 JP 2002522355A5 JP 2000531179 A JP2000531179 A JP 2000531179A JP 2000531179 A JP2000531179 A JP 2000531179A JP 2002522355 A5 JP2002522355 A5 JP 2002522355A5

Authority

JP

Japan

Prior art keywords

thr

leu

ser

asn

gly

Prior art date

1999-02-05

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Granted

Links

• Espacenet
• Global Dossier
• Discuss

• 150000001875 compounds Chemical class 0.000 description 18
• 125000000539 amino acid group Chemical group 0.000 description 9
• 239000008194 pharmaceutical composition Substances 0.000 description 6
• 125000002252 acyl group Chemical group 0.000 description 3
• 206010012601 diabetes mellitus Diseases 0.000 description 3
• FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 2
• 125000004432 carbon atom Chemical group C* 0.000 description 2
• 230000005176 gastrointestinal motility Effects 0.000 description 2
• -1 tert-Leu Chemical compound 0.000 description 2
• CCUAQNUWXLYFRA-IMJSIDKUSA-N Ala-Asn Chemical group C[C@H]([NH3+])C(=O)N[C@H](C([O-])=O)CC(N)=O CCUAQNUWXLYFRA-IMJSIDKUSA-N 0.000 description 1
• BUQICHWNXBIBOG-LMVFSUKVSA-N Ala-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H](C)N BUQICHWNXBIBOG-LMVFSUKVSA-N 0.000 description 1
• 208000002705 Glucose Intolerance Diseases 0.000 description 1
• JWBXCSQZLLIOCI-GUBZILKMSA-N Ile-Leu Chemical group CC[C@H](C)[C@H](N)C(=O)N[C@H](C(O)=O)CC(C)C JWBXCSQZLLIOCI-GUBZILKMSA-N 0.000 description 1
• LCPYQJIKPJDLLB-UWVGGRQHSA-N Leu-Leu Chemical group CC(C)C[C@H](N)C(=O)N[C@H](C(O)=O)CC(C)C LCPYQJIKPJDLLB-UWVGGRQHSA-N 0.000 description 1
• 208000008589 Obesity Diseases 0.000 description 1
• UJTZHGHXJKIAOS-WHFBIAKZSA-N Ser-Gln Chemical group OC[C@H](N)C(=O)N[C@H](C(O)=O)CCC(N)=O UJTZHGHXJKIAOS-WHFBIAKZSA-N 0.000 description 1
• LAFKUZYWNCHOHT-WHFBIAKZSA-N Ser-Glu Chemical compound OC[C@H](N)C(=O)N[C@H](C(O)=O)CCC(O)=O LAFKUZYWNCHOHT-WHFBIAKZSA-N 0.000 description 1
• UQTNIFUCMBFWEJ-IWGUZYHVSA-N Thr-Asn Chemical group C[C@@H](O)[C@H](N)C(=O)N[C@H](C(O)=O)CC(N)=O UQTNIFUCMBFWEJ-IWGUZYHVSA-N 0.000 description 1
• BWUHENPAEMNGQJ-ZDLURKLDSA-N Thr-Gln Chemical group C[C@@H](O)[C@H](N)C(=O)N[C@H](C(O)=O)CCC(N)=O BWUHENPAEMNGQJ-ZDLURKLDSA-N 0.000 description 1
• 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
• XCTHZFGSVQBHBW-IUCAKERBSA-N Val-Leu Chemical group CC(C)C[C@@H](C([O-])=O)NC(=O)[C@@H]([NH3+])C(C)C XCTHZFGSVQBHBW-IUCAKERBSA-N 0.000 description 1
• 150000001413 amino acids Chemical group 0.000 description 1
• 230000009286 beneficial effect Effects 0.000 description 1
• 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
• 208000035475 disorder Diseases 0.000 description 1
• 239000003937 drug carrier Substances 0.000 description 1
• 230000030136 gastric emptying Effects 0.000 description 1
• 201000001421 hyperglycemia Diseases 0.000 description 1
• 108010091798 leucylleucine Proteins 0.000 description 1
• 239000000203 mixture Substances 0.000 description 1
• 235000020824 obesity Nutrition 0.000 description 1
• 201000009104 prediabetes syndrome Diseases 0.000 description 1
• 150000003839 salts Chemical class 0.000 description 1
• 208000011580 syndromic disease Diseases 0.000 description 1
• 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
• 108010036320 valylleucine Chemical group 0.000 description 1